Foghorn Therapeutics Inc. FHTX
We take great care to ensure that the data presented and summarized in this overview for Foghorn Therapeutics Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding FHTX
View all-
Flagship Pioneering Inc. Cambridge, MA12.7MShares$69.8 Million20.03% of portfolio
-
Bvf Inc San Francisco, CA5.3MShares$29.2 Million1.57% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.03MShares$16.7 Million0.52% of portfolio
-
Raymond James & Associates St Petersburg, FL2.3MShares$12.7 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.73MShares$9.54 Million0.0% of portfolio
-
Euclidean Capital LLC New York, NY1.57MShares$8.67 Million1.62% of portfolio
-
Black Rock Inc. New York, NY1.55MShares$8.52 Million0.0% of portfolio
-
Siren, L.L.C. New York, NY721KShares$3.97 Million0.34% of portfolio
-
Geode Capital Management, LLC Boston, MA677KShares$3.73 Million0.0% of portfolio
-
State Street Corp Boston, MA506KShares$2.79 Million0.0% of portfolio
Latest Institutional Activity in FHTX
Top Purchases
Top Sells
About FHTX
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at FHTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 23
2024
|
Carlos Costa Chief People Officer |
SELL
Open market or private sale
|
Direct |
857
-100.0%
|
$8,570
$10.17 P/Share
|
|
Sep 23
2024
|
Carlos Costa Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
857
+50.0%
|
$2,571
$3.72 P/Share
|
|
Sep 20
2024
|
Carlos Costa Chief People Officer |
SELL
Open market or private sale
|
Direct |
35,756
-100.0%
|
$357,560
$10.04 P/Share
|
|
Sep 20
2024
|
Carlos Costa Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
35,756
+50.0%
|
$107,268
$3.72 P/Share
|
|
Sep 18
2024
|
Carlos Costa Chief People Officer |
SELL
Open market or private sale
|
Direct |
11,574
-100.0%
|
$115,740
$10.05 P/Share
|
|
Sep 18
2024
|
Carlos Costa Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,574
+50.0%
|
$34,722
$3.72 P/Share
|
|
Sep 17
2024
|
Carlos Costa Chief People Officer |
SELL
Open market or private sale
|
Direct |
10,272
-100.0%
|
$102,720
$10.04 P/Share
|
|
Sep 17
2024
|
Carlos Costa Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,272
+50.0%
|
$30,816
$3.72 P/Share
|
|
Sep 16
2024
|
Carlos Costa Chief People Officer |
SELL
Open market or private sale
|
Direct |
400
-100.0%
|
$4,000
$10.0 P/Share
|
|
Sep 16
2024
|
Carlos Costa Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
400
+50.0%
|
$1,200
$3.72 P/Share
|
|
Sep 09
2024
|
Steven F. Bellon Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
20,000
-16.4%
|
$180,000
$9.5 P/Share
|
|
Mar 11
2024
|
Fanny Cavalie Chief Strategy/Bus Ops Officer |
SELL
Open market or private sale
|
Direct |
11,000
-12.64%
|
$66,000
$6.56 P/Share
|
|
Aug 17
2023
|
Adrian Gottschalk Chief Executive Officer |
BUY
Bona fide gift
|
Indirect |
63,000
+10.96%
|
-
|
|
Aug 17
2023
|
Adrian Gottschalk Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
63,000
-100.0%
|
-
|
|
Aug 16
2023
|
Samuel Agresta Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
311,297
-100.0%
|
$2,490,376
$8.25 P/Share
|
|
Aug 16
2023
|
Samuel Agresta Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
311,297
+50.0%
|
$933,891
$3.72 P/Share
|
|
May 26
2023
|
Adrian Gottschalk Chief Executive Officer |
BUY
Bona fide gift
|
Indirect |
300,000
+40.07%
|
-
|
|
May 26
2023
|
Adrian Gottschalk Chief Executive Officer |
SELL
Bona fide gift
|
Indirect |
300,000
-40.07%
|
-
|
|
Feb 17
2023
|
Adrian Gottschalk Chief Executive Officer |
BUY
Other acquisition or disposition
|
Indirect |
184,939
+29.19%
|
-
|
|
Feb 17
2023
|
Adrian Gottschalk Chief Executive Officer |
SELL
Other acquisition or disposition
|
Indirect |
184,939
-29.19%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 58.9K shares |
|---|
| Open market or private sale | 89.9K shares |
|---|